Genetic Engineering & Biotechnology News - Biotechnology from Bench to Business". ↑ "News: Quark Pharmaceuticals Inks a Deal to Advance Preclinical Pipeline of Hearing Loss Compounds.↑ "Life Sciences World - LifeSciencesWorld is your online resource for health, medical devices and life sciences industries".Presented Positive Preclinical Results Of Systemic RNAi Compound For Acute Renal Failure (ARF)". ↑ "Quark Pharmaceuticals to grow in Boulder".
QUARK PHARMACEUTICALS LICENSE
Antisense RNA produced intracellularly by an expression vector may be developed and find utility as novel therapeutic agents. RNAi is now known as precise, efficient, stable and better than antisense therapy for gene suppression. Since the discovery of RNAi and its regulatory potentials, it has become evident that RNAi has immense potential in suppression of desired genes. Mello shared the 2006 Nobel Prize in Physiology or Medicine for their work on RNA interference in the nematode worm Caenorhabditis elegans, which they published in 1998. The detailed study of each of these seemingly different processes elucidated that the identity of these phenomena were all actually RNAi. Historically, RNAi was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. RNA interference ( RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. This finding suggested that by inhibiting this gene, a therapeutic effect could be obtained in the treatment of cancer and other pathologies involving hypoxia. In 2004, peer-reviewed journal Oncogene reported that Quark discovered the role of gene Ero-1L alpha in protein secretion under hypoxic condition.
QUARK PHARMACEUTICALS TRIAL
Reports results for PF-655 (formerly PF-04523655 or RTP801I-14) from a Phase II trial in patients with diabetic macular edema.To develop QPI-1007 for India and other key markets. Enters into a license and collaboration agreement with Biocon Ltd.The JV will develop QPI-1007 for China and other markets. Establishes a Chinese joint venture with Suzhuo and raises RMB45 million for the joint venture.On August 1, 2021, Quark closed up operations in the United States.Quark Pharmaceuticals is a pharmaceutical company that develops RNA interference-based treatments for chronic and acute diseases.